drugset / Trial / NCT06827249
Peginterferon α-2b Injection for the Treatment of Pediatric RSV Bronchiolitis
RandomizedCrossoverTriple-blindTreatment
Summary
This is a multicenter, randomized, positive-controlled, non-inferiority clinical study, planning to enroll 90 children with bronchiolitis caused by respiratory syncytial virus infection, to evaluate the safety and efficacy of inhaled Peginterferon α-2b injection compared to recombinant human interferon α2b in the treatment of pediatric respiratory syncytial virus bronchiolitis.
Timeline
- Start
- 2025-03
- Primary completion
- 2026-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon α-2b | Protein / enzyme biologic | 90 ug | Inhaled |
| Comparator | Recombinant Human Interferon α2b | Protein / enzyme biologic | 100000 iu/kg | Inhaled |